Evolution of HER2-low expression from primary to recurrent breast cancer

• Published in: NPJ breast cancer Vol. 7; no. 1; pp. 137 - 8
• Main Authors: Miglietta, Federica, Griguolo, Gaia, Bottosso, Michele, Giarratano, Tommaso, Lo Mele, Marcello, Fassan, Matteo, Cacciatore, Matilde, Genovesi, Elisa, De Bartolo, Debora, Vernaci, Grazia, Amato, Ottavia, Conte, PierFranco, Guarneri, Valentina, Dieci, Maria Vittoria
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 12.10.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4028/67/1347; 692/4028/67/1857; 692/4028/67/322; Biomedical and Life Sciences; Biomedicine; Biopsy; Breast cancer; Cancer Research; Cancer therapies; Cell Biology; Chemotherapy; Clinical medicine; Evolution; Gene amplification; Gene expression; Genotype & phenotype; Human Genetics; Medical research; Metastasis; Oncology; Pathology; Tumors
• ISSN: 2374-4677; 2374-4677
• DOI: 10.1038/s41523-021-00343-4

About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low category in both primary and recurrent BC sample...